Diagnostic use of highly toxic amyloid oligomers

• Main Authors: JI SHAOYANG, YU XIAOLIN, LIU RUITIAN, HUANG YARU, XIE XIXIU
• Format: Patent
• Language: Chinese; English
• Published: 23.02.2024
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

The invention relates to a diagnostic use of highly toxic amyloid oligomers. Specifically, the present invention relates to the use of a novel highly toxic amyloid oligomer A [beta] o * 3F, specifically bound by a 3F antibody, in the cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, as a target for the diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD. 本发明涉及强毒性淀粉样蛋白寡聚体的诊断用途。具体而言，本发明涉及新的强毒性淀粉样蛋白寡聚体Aβo*3F作为靶标用于诊断早期和中晚期阿尔茨海默病(AD)及AD源性轻度认知障碍(MCI)的用途，所述Aβo*3F被3F抗体特异性结合，存在